ARS Pharmaceuticals (SPRY) Receivables (2023 - 2026)

ARS Pharmaceuticals has reported Receivables for 4 years, with the latest figure at $28.7 million in Q1 2026.

• Quarterly Receivables rose 179.19% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.7 million (up 179.19% YoY) and the FY2025 annual result came in at $25.3 million, up 169.45% from the prior year.
• Receivables rose to $28.7 million in Q1 2026 per SPRY's latest filing, from $25.3 million in the prior quarter.
• Over five years, Receivables peaked at $40.7 million in Q3 2025 and troughed at $652000.0 in Q4 2023.
• A 4-year average of $17.9 million and a median of $17.8 million in 2025 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 4394.48% in 2025, down 169.45% in 2025.
• Over 4 years, Receivables stood at $652000.0 in 2023, then surged by 1342.79% to $9.4 million in 2024, then soared by 169.45% to $25.3 million in 2025, then advanced by 13.08% to $28.7 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $28.7 million, $25.3 million, and $40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.